Differential Expression of Inflammasome-Related Genes in Induced Pluripotent Stem-Cell-Derived Retinal Pigment Epithelial Cells with or without History of Age-Related Macular Degeneration.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
24 Jun 2021
Historique:
received: 21 05 2021
revised: 16 06 2021
accepted: 21 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Inflammation is a key underlying factor of age-related macular degeneration (AMD) and inflammasome activation has been linked to disease development. Induced pluripotent stem-cell-derived retinal pigment epithelial cells (iPSC-RPE) are an attractive novel model system that can help to further elucidate disease pathways of this complex disease. Here, we analyzed the effect of dysfunctional protein clearance on inflammation and inflammasome activation in iPSC-RPE cells generated from a patient suffering from age-related macular degeneration (AMD) and an age-matched control. We primed iPSC-RPE cells with IL-1α and then inhibited both proteasomal degradation and autophagic clearance using MG-132 and bafilomycin A1, respectively, causing inflammasome activation. Subsequently, we determined cell viability, analyzed the expression levels of inflammasome-related genes using a PCR array, and measured the levels of pro-inflammatory cytokines IL-1β, IL-6, IL-8, and MCP-1 secreted into the medium. Cell treatments modified the expression of 48 inflammasome-related genes and increased the secretion of mature IL-1β, while reducing the levels of IL-6 and MCP-1. Interestingly, iPSC-RPE from an AMD donor secreted more IL-1β and expressed more Hsp90 prior to the inhibition of protein clearance, while MCP-1 and IL-6 were reduced at both protein and mRNA levels. Overall, our results suggest that cellular clearance mechanisms might already be dysfunctional, and the inflammasome activated, in cells with a disease origin.

Identifiants

pubmed: 34202702
pii: ijms22136800
doi: 10.3390/ijms22136800
pmc: PMC8268331
pii:
doi:

Substances chimiques

Biomarkers 0
Cytokines 0
HSP90 Heat-Shock Proteins 0
Inflammasomes 0
Inflammation Mediators 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Academy of Finland
ID : 315085
Organisme : Academy of Finland
ID : 296840
Organisme : Academy of Finland
ID : 297267
Organisme : Academy of Finland
ID : 328443
Organisme : Emil Aaltosen Säätiö
ID : N/A
Organisme : Sigrid Juseliuksen Säätiö
ID : N/A
Organisme : Mary och Georg C. Ehrnrooths Stiftelse
ID : N/A
Organisme : Kuopion Yliopistollinen Sairaala
ID : 5503743
Organisme : Suomen Silmäsäätiö
ID : N/A
Organisme : Päivikki ja Sakari Sohlbergin Säätiö
ID : N/A

Références

Int J Mol Sci. 2017 May 19;18(5):
pubmed: 28534814
Cell. 2012 May 11;149(4):847-59
pubmed: 22541070
Redox Biol. 2017 Oct;13:255-265
pubmed: 28600982
Cell Physiol Biochem. 2018;49(1):359-367
pubmed: 30138927
Int J Mol Sci. 2019 Aug 01;20(15):
pubmed: 31375001
Oxid Med Cell Longev. 2019 Mar 17;2019:1583656
pubmed: 31007832
Stem Cell Res Ther. 2017 Dec 29;8(1):291
pubmed: 29284513
Sci Rep. 2018 Apr 30;8(1):6720
pubmed: 29712950
Trends Mol Med. 2020 Jan;26(1):105-118
pubmed: 31771932
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):493-497
pubmed: 28906084
Int J Mol Sci. 2019 Jan 08;20(1):
pubmed: 30626110
Stem Cells Transl Med. 2020 Dec;9(12):1585-1603
pubmed: 32815311
Cell. 2017 Nov 16;171(5):1057-1071.e11
pubmed: 29033131
Arch Ophthalmol. 2005 Jun;123(6):774-82
pubmed: 15955978
Invest Ophthalmol Vis Sci. 2015 May;56(5):3371-82
pubmed: 26024122
Mol Ther. 2015 Nov;23(11):1700-1711
pubmed: 26300224
PLoS One. 2013 Jun 19;8(6):e66978
pubmed: 23840568
Neurobiol Aging. 2006 Jul;27(7):983-93
pubmed: 15979212
Cell Rep. 2018 Jan 2;22(1):189-205
pubmed: 29298421
Mediators Inflamm. 2015;2015:690243
pubmed: 25698849
Prog Retin Eye Res. 2020 Nov;79:100858
pubmed: 32298788
J Transl Med. 2016 Dec 20;14(1):344
pubmed: 27998274
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
Oxid Med Cell Longev. 2020 Feb 10;2020:7901270
pubmed: 32104539
J Leukoc Biol. 2015 Nov;98(5):713-25
pubmed: 26292978
Hum Mol Genet. 2013 Feb 1;22(3):593-607
pubmed: 23139242
Sci Rep. 2018 Jan 11;8(1):461
pubmed: 29323137
Mol Ther. 2014 Sep;22(9):1688-97
pubmed: 24895994
J Clin Med. 2015 Jan 14;4(1):172-92
pubmed: 26237026
Invest Ophthalmol Vis Sci. 2013 Jan 07;54(1):110-20
pubmed: 23221073
Nat Rev Immunol. 2013 Jun;13(6):438-51
pubmed: 23702979
Cell Mol Life Sci. 2016 May;73(9):1765-86
pubmed: 26852158
Mol Vis. 2010 Jul 27;16:1399-414
pubmed: 20680098
Sci Rep. 2015 Aug 11;5:12910
pubmed: 26263531
Cell Stem Cell. 2013 Dec 5;13(6):691-705
pubmed: 24315443
Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4289-97
pubmed: 20357205
Cell Stem Cell. 2017 May 4;20(5):635-647.e7
pubmed: 28132833
PLoS One. 2011;6(8):e22818
pubmed: 21850237
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5934-43
pubmed: 19578022
Cell Mol Life Sci. 2020 Mar;77(5):779-780
pubmed: 31897540
Adv Exp Med Biol. 2019;1186:33-53
pubmed: 31654385
J Neurosci. 2015 May 6;35(18):7304-11
pubmed: 25948278
Front Aging Neurosci. 2019 Oct 22;11:286
pubmed: 31695606
Front Mol Neurosci. 2018 Nov 06;11:401
pubmed: 30459553
Curr Mol Med. 2010 Dec;10(9):802-23
pubmed: 21091424
Adv Exp Med Biol. 2016;854:549-55
pubmed: 26427458
J Res Med Sci. 2019 Mar 25;24:24
pubmed: 31007694
Biochim Biophys Acta. 2014 Dec;1843(12):3038-46
pubmed: 25268952
EMBO Mol Med. 2013 Nov;5(11):1775-93
pubmed: 24142887
Hum Mol Genet. 2014 Jul 1;23(13):3445-55
pubmed: 24497574
Am J Ophthalmol. 2007 Apr;143(4):607-15
pubmed: 17280640
Mol Immunol. 2009 Apr;46(7):1374-86
pubmed: 19157552
Graefes Arch Clin Exp Ophthalmol. 2015 May;253(5):699-704
pubmed: 25056526
Stem Cells. 2017 Nov;35(11):2305-2320
pubmed: 28913923
Nat Med. 2018 Jan;24(1):50-61
pubmed: 29176737
Ophthalmic Res. 2006;38(4):182-8
pubmed: 16679805
Am J Ophthalmol. 2013 Dec;156(6):1176-83
pubmed: 24083687

Auteurs

Maria Hytti (M)

Immuno-Ophthalmology, School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.

Eveliina Korhonen (E)

Immuno-Ophthalmology, School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.
Department of Clinical Chemistry, HUSLAB, Helsinki University Hospital, 00029 Helsinki, Finland.

Heidi Hongisto (H)

Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.
Ophthalmology, School of Medicine, University of Eastern Finland, 70210 Kuopio, Finland.

Kai Kaarniranta (K)

Ophthalmology, School of Medicine, University of Eastern Finland, 70210 Kuopio, Finland.
Department of Ophthalmology, Kuopio University Hospital, 70029 Kuopio, Finland.

Heli Skottman (H)

Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.

Anu Kauppinen (A)

Immuno-Ophthalmology, School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH